166. A Phase 2b/3 Study to Evaluate the Efficacy and Safety of an Investigational Respiratory Syncytial Virus (RSV) Antibody, Clesrovimab, in Healthy Preterm and Full-Term Infants
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.003
Abstract: Abstract Background Clesrovimab is an investigational, long-acting monoclonal antibody (mAb) targeting site IV of the fusion protein for the prevention of RSV lower respiratory tract infection in infants. Methods This phase 2b/3 double-blind, randomized, placebo-controlled… read more here.
Keywords: rahway usa; merck; merck inc; merck sharp ... See more keywords